Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance
· smallcaps.com.au
Aroa Biosurgery beats FY26 guidance as Myriad drives revenue 23% YoY; FY27 targets NZ$115-125m, Symphony catalyst; cash-rich, debt-free.
Aroa Biosurgery (ASX: ARX) has reported FY26 results that significantly exceeded revenue and EBITDA guidance, driven by strong Myriad growth and a robust produc...